Dose-response characteristics in adolescents with attention-deficit/ hyperactivity disorder treated with OROS® methylphenidate in a 4-week, open-label, dose-titration study

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 3, 2010, Pages 187-196

  Newcorn, Jeffrey H ^a   Stein, Mark A ^b   Cooper, Kimberly M ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c McNeil Pediatrics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; OROS; PLACEBO; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE; ANALYSIS OF VARIANCE; ANOREXIA; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; OPEN STUDY; PREDICTION; REGRESSION ANALYSIS; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHYLPHENIDATE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77954902926     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0102     Document Type: Article

References (44)

1. Adler L, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T: Efficacy and safety of OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 29:239-247, 2009.
2. American Academy of Pediatrics: Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Committee on Quality Improvement, Subcommittee on Atten-tion-Deficit/ Hyperactivity Disorder. Pediatrics 105; 1158-1170. 2000.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DMS-IV).Washington (DC): American Psychiatric Association, 1994.
4. Barkley RA, Fischer M, Edelbrock CS, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546-557, 1990. (Pubitemid 20235340)
5. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J: A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53:437-446, 1996.
6. Biederman J, Mick E, Faraone SV: Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 157:816-818, 2000.
7. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM, Greiner AR, Altenderfer L, Baron-Myak C: Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol 9:163-175, 2001.
8. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J: Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 24: 24-29, 2004.
9. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:107-115, 2001.
10. Findling RL, Dogin JW: Psychopharmacology of ADHD: Children and adolescents. J Clin Psychiatry 59:42-49, 1998.
11. Findling RL, Short EJ, Manos MJ: Developmental aspects of psy-chostimulant treatment in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 40:1441-1447, 2001.
12. Goldman LS, Myron G, Bezman RJ, Slanetz PJ: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 279:1100-1107, 1998.
13. Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells K: Medication treatment strategies in the MTA study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 35:1304-1313, 1996.
14. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T: Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 40:180-187, 2001.
15. Greenhill L, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, Gillberg C, Huss M, Jensen P, Kennedy JL, Klein R, Rapoport J, Sagvolden T, Spencer T, Swanson JM, Volkow N: Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. J Atten Disord 6(Suppl 1): S89-S100, 2002a.
16. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S; American Academy of Child and Adolescent Psychiatry: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41:26S-49S, 2002b.
17. Greydanus DE, Sloan MA, Rappley MD: Psychopharmacology of ADHD in adolescents. Adolesc Med 13:599-624, 2002.
18. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ: Developmental changes in attention-deficit hyperactivity disorder in boys: A four-year longitudinal study. J Abnorm Child Psychol 23:729-749, 1995.
19. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
20. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, Lee E, Buitelaar JK: A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 63:981-989, 2008.
21. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp, NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperac-tivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
22. Olfson M, Gameroff MJ, Marcus ST, Jensen PS: National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 160:1071-1077, 2003.
23. Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T: Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 71:540-552, 2003.
24. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001.
25. Rapport MD, Denney C, DuPaul GJ, Gardner MJ: Attention deficit disorder and methylphenidate: Normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 33:882-893, 1994.
26. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
27. Smith BH, Waschbusch DA, Willoughby MT, Evans S: The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/ hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 3:243-267, 2000.
28. Spencer TJ: ADHD treatment across the life cycle. J Clin Psychiatry 65:22-26, 2004.
29. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K: A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperac-tivity disorder. Arch Gen Psychiatry 52:434-443, 1995.
30. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention-deficit/hyperactivity disorder. Can J Clin Pharmacol 13: e50-e62, 2006.
31. Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K, Doyle R, Parekh A, Kagan J, Bearman SK. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 58:775-782, 2001.
32. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L; Adult ADHD Research Group: Efficacy and safety of dexmethyl-phenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 61:1380-1387, 2007.
33. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention-deficit/hyperactivity disorder. Can J Clin Pharmacol 13: e50-e62, 2006.
34. Stein MA: OROS® methylphenidate for treatment of adolescents and adults with ADHD. Miami (Florida): American Academy of Child and Adolescent Psychiatry (AACAP) 50th Anniversary Meeting, 2003 (poster).
35. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose-response study of OROS methylphenidate in children with attention-deficit/hy-peractivity disorder. Pediatrics 112:E404-E413, 2003.
36. Swanson J, Greenhill L, Pelham W, Wilens T, Wolraich M, Abikoff H, Atkins M, August G, Biederman J, Bukstein O, Conners CK, Efron L, Fiebelkorn K, Fried J, Hoffman M, Lambrecht L, Lerner M, Leventhal B, McBurnett K, Morse E, Palumbo D, Pfiffner L, Stein M, Wigal S, Winans E: Initiating Concerta (OROS® meth-ylphenidate HCl) qd in children with attention-deficit hyperactivity disorder. J Clin Res 3:59-76, 2000.
37. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Linde-mulder E, Wigal S: Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperac-tivity disorder. Arch Gen Psychiatry 60:204-211, 2003.
38. Taylor FB, Russo J: Efficacy of modafinil compared to dextroam-phetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 10:311-320, 2000.
39. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 21:223-228, 2001.
40. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, Read SC, Tulloch SJ: Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial. CNS Spectr 11:625-639, 2006.
41. Wilens TE, Spencer TJ: The stimulants revisited. Child Adolesc Psychiatry Clin N Am 9:573-603, 2000.
42. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M: ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44:1015-1023, 2005.
43. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM: Multisite, controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pe-diatr Adolesc Med 160:82-90, 2006.
44. Wolraich M, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883-892,2001.